The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XW003 injection in Chinese adolescents with obesity
In this study, eligible participants will be randomized into one of the three cohorts in a 3:1 ratio to receive either once-weekly subcutaneous XW003 injection or placebo, for up to 20 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
48
Subcutaneous injection
Subcutaneous injection
Qilu Hospital of Shandong University
Jinan, Shandong, China
Number and severity of adverse events
Time frame: week 20
Plasma concentrations of XW003
Time frame: week 20
Change of body weight from baseline
Time frame: week 20
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.